

CURRICULUM VITAE

William Stuart Asch, MD/PhD, BA

Version Date: 10/17/2023

Contact Information:

Address 330 Cedar Street
Ste Suite 117
New Haven, CT 06510
Phone: 1 (203) 785-6781
Email: william.asch@yale.edu

School: Yale School of Medicine

Education:

xxxx - 01/1993 BA, Brandeis University, Waltham, MA
xxxx - 01/2001 MD/PhD, SUNY at Stonybrook, Stony Brook, NY

Career/Academic Appointments:

07/2001 - 06/2002 Intern, Internal Medicine, Yale New Haven Hospital, New Haven, CT
07/2002 - 06/2004 Junior and Senior Resident, Internal Medicine, Yale New Haven Hospital, New Haven, CT
07/2002 - 06/2004 Resident, Internal Medicine, Yale-New Haven Hospital, New Haven, CT
07/2004 - 06/2008 Clinical Fellow, Nephrology (Medicine), Yale School of Medicine, New Haven, CT
07/2004 - 06/2008 Fellow, Nephrology, Yale University School of Medicine, New Haven, CT
07/2008 - 06/2017 Assistant Professor, Nephrology (Medicine), Yale School of Medicine, New Haven, CT
07/2016 - 06/2017 Assistant Professor, Transplant, Yale School of Medicine, New Haven, CT
07/2017 - 06/2027 Associate Professor on Term, Nephrology (Medicine), Yale School of Medicine, New Haven, CT

Administrative Positions:

2011 - Present Director of Pre-Transplant Operations, Internal Medicine, Yale New Haven Hospital, New Haven, CT
2015 - Present Program Director, Transplant Nephrology Fellowship Program, Internal Medicine, Yale University, New Haven, CT

Board Certification:

2004 - 2015 AB of Internal Medicine, Internal Medicine
2015 - 2023 AB of Internal Medicine, Internal Medicine, recertification
2006 - 2016 AB of Internal Medicine, Nephrology
2016 - 2023 AB of Internal Medicine, Nephrology, recertification

Professional Honors & Recognition:

International/National/Regional

1993 Undergraduate Honors Thesis Award
1997 Excellence in Graduate Research Award, Nominee
2006 National Kidney Foundation Fellowship Training Award
2022 Fellow, American Society of Transplantation (AST)

Yale University/Yale School of Medicine/Hospital System

2009 Leonard Tow Humanism in Medicine Award, Nominee

Grants/Clinical Trials History:

Current Clinical Trials

Agency: Atara Biotherapeutics, Inc.
I.D.#: 2000021894
Title: Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 01/25/2018 - ongoing

Agency: ProKidney
I.D.#: 2000021970
Title: A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 02/01/2018 - ongoing

Agency: Medeor Therapeutics, Inc.
I.D.#: 2000022339

Title: A Phase 3 Prospective, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants

P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 07/11/2018 - ongoing

Agency: Yale University School of Medicine
I.D.#: 2000025513
Title: Diagnostic Renal Pathology by Multiphoton Microscopy
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/04/2019 - ongoing

Agency: Medeor Therapeutics, Inc.
I.D.#: 2000032243
Title: Extension Study to Assess the Long-Term Safety in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 04/17/2022 - ongoing

Agency: Memo Therapeutics
I.D.#: 2000034575
Title: Safety, tolerability and efficacy of AntiBKV as treatment of BKV infection in kidney transplant recipients, a randomized phase II/III study, double-blind and placebo-controlled
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 05/08/2023 - ongoing

Agency: Cedars-Sinai Medical Center
I.D.#: 2000033724
Title: RTB-015 (ABCs Trial): ASSESSMENT OF BIOMARKER-GUIDED CNI SUBSTITUTION IN KIDNEY TRANSPLANTATION
P.I.: Richard Formica

Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/25/2023 - ongoing

Past Clinical Trials

Agency: Bristol-Myers Squibb Company
I.D.#: 0510000745
Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial
P.I.: Richard Formica
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/01/2006 - 08/03/2015

Agency: Pfizer Inc., U.S. Pharmaceuticals Group
I.D.#: 0810004381
Title: A Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial to Evaluate the Long-Term Safety and Efficacy of CP-690,550 in Renal Allograft Recipients
P.I.: Sanjay Kulkarni
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 11/21/2008 - 11/03/2015

Agency: LifeCycle Pharma A/S
I.D.#: 1011007691
Title: A PHASE 3, DOUBLE-BLIND, DOUBLE-DUMMY, MULTI-CENTER, PROSPECTIVE, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF LCP-TACRO TABLETS, ONCE DAILY, COMPARED TO PROGRAF CAPSULES, TWICE DAILY, IN COMBINATION WITH MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE ALLOGRAFT REJECTION IN DE NOVO ADULT KIDNEY TRANSPLANT RECIPIENTS
P.I.: Sanjay Kulkarni
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 12/16/2010 - 07/24/2014

Agency: Mount Sinai School of Medicine
I.D.#: 1012007781

Title: Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplants
P.I.: Richard Formica
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/02/2011 - 09/13/2016

Agency: Bristol-Myers Squibb Company
I.D.#: 1202009753REG
Title: Evaluating Nulojix Long Term Safety in Transplant - Enlist Registry
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/21/2012 - 06/25/2019

Agency: Veloxis Pharmaceuticals A/S
I.D.#: 1201009573
Title: Switching Study of Kidney Transplant Patients with Tremor to LCP_TACRO (STRATO)
P.I.: Richard Formica
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 03/02/2012 - 08/19/2015

Agency: Astellas Pharma US, Inc.
I.D.#: 1201009513
Title: Phase 2/3 Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de novo Kidney Transplant Recipients
P.I.: Sanjay Kulkarni
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/03/2012 - 02/15/2013

Agency: Viropharma Inc.
I.D.#: 1307012405
Title: A Phase 2, Randomized Study To Assess The Safety And Anti Cytomegalovirus (CMV) Activity Of Different Doses Of Maribavir For Treatment Of CMV Infections That Are Resistant Or Refractory To Treatment With Ganciclovir/Valganciclovir Or Foscarnet In Transplant Recipients (#1263-202, Amendment 1, 18May2012)

P.I.: Maricar Malinis
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 08/21/2013 - 09/18/2014

Agency: Icahn School of Medicine at Mount Sinai (ISMMS)
I.D.#: 1405014029
Title: Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation

P.I.: Sanjay Kulkarni
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/03/2014 - 04/10/2018

Agency: George M. O'Brien Center for Kidney Research
I.D.#: 1405014040
Title: Protocol Biopsy Study for Biomarkers and Histology in Kidney Transplant Recipients

P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 07/16/2014 - 07/10/2018

Agency: Bristol-Myers Squibb Company
I.D.#: 1406014090
Title: Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

P.I.: Richard Formica
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/08/2014 - 08/16/2019

Agency: Chimerix, Inc.
I.D.#: 1508016367
Title: SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients (BCV CMV vGCV)

P.I.: Maricar Malinis

Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/16/2015 - 09/06/2016

Agency: Chimerix, Inc.
I.D.#: 1508016368
Title: SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)

P.I.: Maricar Malinis
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/16/2015 - 09/06/2016

Agency: Yale University School of Medicine
I.D.#: 1604017584REG
Title: CAB - Cognition After Belatacept Conversion
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 05/02/2016 - 03/10/2022

Agency: Astellas Pharma US, Inc.
I.D.#: 1608018292
Title: To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)
P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 10/17/2016 - 03/17/2020

Agency: CSL Behring LLC
I.D.#: 2000021183
Title: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
P.I.: William Asch
Role: Principal Investigator

Percent effort: N/A
Total costs: -
Project period: 10/02/2017 - 10/23/2020

Agency: Hookipa Biotech AG
I.D.#: 2000023413
Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Negative Recipient (R-) Patients Awaiting Kidney Transplantation from CMV-Positive Donors (D+)

P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 02/06/2019 - 06/16/2021

Agency: Atara Biotherapeutics, Inc.
I.D.#: 2000024159
Title: Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 07/14/2019 - 07/19/2023

Agency: Amplyx Pharmaceuticals, Inc.
I.D.#: 2000027583
Title: A randomized, double blind, placebo-controlled study to assess the safety and efficacy of MAU868 for the treatment of BK viremia in kidney transplant recipients

P.I.: William Asch
Role: Principal Investigator
Percent effort: N/A
Total costs: -
Project period: 05/26/2020 - 08/22/2022

Pending Clinical Trials

Agency: National Human Genome Research Institute (NHGRI)
I.D.#: 9512008556
Title: Genetics of Familial Electrolyte and Glucose Imbalances, Mineral Metabolism, Blood Pressure, Mitochondrial Function and Renal Disease Including IgA Nephropathy, Henoch-Schonlein Purpura [HSP], nephrocalcinosis [kidney stones] and End Stage Renal Disease

P.I.: Richard Lifton
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 11/30/1995 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale: International/National

1. ""Kidney Transplant for the Elderly: Hope or Hype?"". University of Cincinnati, "Kidney Transplant for the Elderly: Hope or Hype?", Cincinnati, OH, January 2014. (Lecture)
2. "Yale BK Surveillance Monitoring Data". New England BK Virus Consortium, Yale BK Surveillance Monitoring Data, Waltham, MA, January 2015. (Oral Presentation)
3. "Kidney Transplant for the Elderly: Hope or Hype". University of Massachusetts Worcester, Kidney Transplant for the Elderly: Hope or Hype, Worcester, MA, January 2015. (Lecture)
4. "The Infusion with a Difference: Patient and Center Experiences with Belatacept after 100 Conversions". Rhode Island Hospital, Division of Organ Transplantation, The Infusion with a Difference: Patient and Center Experiences with Belatacept after 100 Conversions, Providence, RI, January 2018. (Lecture)

Regional

1. "Assessment of Recipient Readiness for Kidney Transplantation". American Nephrology Nurses Association, Southern New England Chapter Annual Meeting, Lecturer, Assessment of Recipient Readiness for Kidney Transplantation, Ledyard, CT, January 2018. (Lecture)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. New England BK Consortium: Regional Survey of BK Screening and Management Protocols in Comparison to Published Consensus Guidelines. American Society of Transplantation, New England BK Consortium: Regional Survey of BK Screening and Management Protocols in Comparison to Published Consensus Guidelines, Boston, MA, January 2016. (Poster Presentation)

Professional Service:

Journal Services

Editorial boards

2016 - Present Editor, Journal of Onco-Nephrology
2017 - Present Editor, Clinical J. of the American Society of Nephrology

Reviewer

2008 - Present Reviewer, American Journal of Transplantation
2008 - Present Reviewer, Transplantation

2012 - 2017 Reviewer, Clinical J. of the American Society of Nephrology
2020 - Present Reviewer, Clinical Transplantation

Professional Organizations

American Society of Nephrology

2004 - 2008 Member, American Society of Nephrology

American Society of Transplantation

2009 - Present Member, American Society of Transplantation
2021 - Present Co-Chair, American Society of Transplantation, The American Society of Transplantation Education Committee oversees the varied educational resources and activities provided by the Society. The "Timely Topics Transplantation" webinars, "Comprehensive Trainee Curriculum" videos, AST Journal clubs, and "Transplant in 10 (minutes)" videos are examples of the output from the Ed Committee. In addition, any manuscript born out of an AST committee or COP (Community of Practice) wishing to be labeled as a "Work Product" of the AST is reviewed by the Ed committee prior to journal submission.

American Society of Transplantation Education Committee

2020 - Present Committee Member, American Society of Transplantation Education Committee, Elected to the Education Committee of the American Society of Transplantation

New England BK Consortium (NEBKCON)

2015 - Present Founding Member, New England BK Consortium (NEBKCON)

Society for Neurosciences

1998 - 2001 Member, Society for Neurosciences

Yale University / Hospital System

University

2009 - Present Representative, Nephrology Diversity Committee

Department

2008 - Present Member, Donor Advocacy Panel, Yale New Haven Hospital Transplantation Center
2008 - Present Board Member, Medical Review Board, Yale New Haven Hospital Transplantation Center
2014 - Present Committee Member, Kidney/Pancreas Transplant Program QA/PI
2021 Chairperson, Committee to Review Use of eGFR Race Modifier, Beginning in the Spring of 2020, Drs. Gary Desir and Aldo Peixoto tasked the Section of Nephrology to critically review our institutions continued use of the eGFR Race Modifier. Dr.

Doug Smith chaired this committee at its inception and until his retirement in January 2021. Subsequently, I was selected to lead this committee in the Spring of 2021. I chaired an interim meeting in May 2021 following the release of the Phase 1 report from the NKF-ASN Task Force evaluating this issue. Our committee voted to follow the Task Force's instruction to wait for publication of the Phase 2 report recommendations. When the publication of the Phase 2 report was significantly delayed, our committee moved forward and recommended that the clinical lab report eGFR without use of the Race Modifier. This recommendation will be reviewed by stakeholders across the Yale Health System and discussed at an upcoming meeting scheduled for October 19, 2021.

Hospital

2007 - 2010	Committee Member, Pharmacy and Therapeutics Committee
2010 - Present	Committee Member, Pharmacy and Therapeutics Committee
2013 - Present	Committee Member, Transplant Operations Council

Public Service / Media Presence

Public Service

2008	Participant, Polycystic Kidney Foundation CT Chapter Meeting
2009	Participant, Polycystic Kidney Foundation NY Regional Meeting
2009	Volunteer, National Kidney Foundation KEEP Program
2009	Volunteer, Donate Life
2022 - 2024	Representative, Organ Procurement and Transplantation Network (OPTN), I am currently the UNOS Region 1 representative on the Organ Procurement and Transplantation Network (OPTN) Pancreas Committee. The OPTN is a branch of the Health Resources and Services Administration (HRSA). It is a special time to be serving on this committee. The major goal is to redesign the donor pancreata allocation system in the United States. This is a multi-year project that is nearing completion. Our recent meetings have focused on the review of the organ allocation simulations generated by the Scientific Registry of Transplant Recipients (SRTR). Based on the output, refinements to the model are suggested to maximize the allocation goals (e.g. reduce geographic disparity, improve highly sensitized candidate access to organs).

Bibliography:

Peer-Reviewed Original Research

1. Passini M, Kurtzman A, Canger A, **Asch W**, Wray G, Raymond P, Schechter N. Cloning of zebrafish vsx1: Expression of a paired-like homeobox gene during CNS development. *Genesis* 1998, 23: 128-141. [PMID: 9770270](https://pubmed.ncbi.nlm.nih.gov/9770270/), [3.0.co;2-8" target=" blank">DOI: 10.1002/\(sici\)1520-6408\(1998\)23:2<128::aid-dvg5>3.0.co;2-8.](https://pubmed.ncbi.nlm.nih.gov/9770270/)
2. **Asch W**, Leake D, Canger A, Passini M, Argenton F, Schechter N. Cloning of Zebrafish Neurofilament cDNAs for Plasticin and Gefiltin: Increased mRNA Expression in Ganglion Cells After Optic Nerve

- Injury. Journal Of Neurochemistry 1998, 71: 20-32. [PMID: 9648847](#), [DOI: 10.1046/j.1471-4159.1998.71010020.x](#).
3. Canger A, Passini M, **Asch W**, Leake D, Zafonte B, Glasgow E, Schechter N. Restricted expression of the neuronal intermediate filament protein plasticin during zebrafish development. The Journal Of Comparative Neurology 1998, 399: 561-572. [PMID: 9741483](#), [3.0.co;2-#" target=" blank">DOI: 10.1002/\(sici\)1096-9861\(19981005\)399:4<561::aid-cne8>3.0.co;2-#](#).
 4. Leake D, **Asch W**, Canger A, Schechter N. Gefiltin in zebrafish embryos: sequential gene expression of two neurofilament proteins in retinal ganglion cells. Differentiation 1999, 65: 181-189. [PMID: 10653354](#), [DOI: 10.1046/j.1432-0436.1999.6540181.x](#).
 5. **Asch WS**, Schechter N. Plasticin, a Type III Neuronal Intermediate Filament Protein, Assembles as an Obligate Heteropolymer. Journal Of Neurochemistry 2000, 75: 1475-1486. [PMID: 10987827](#), [DOI: 10.1046/j.1471-4159.2000.0751475.x](#).
 6. **Asch W**, Lifton R. Chapter 14 Molecular Genetics of Magnesium Homeostasis. 2009, 249-261. [DOI: 10.1016/b978-0-12-449851-8.00014-0](#).
 7. Formica RN, **Asch WS**, Wagner KR, Kulkarni S. Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information? Clinical Journal Of The American Society Of Nephrology 2010, 5: 924-928. [PMID: 20203162](#), [PMCID: PMC2863980](#), [DOI: 10.2215/cjn.06820909](#).
 8. Barrantes F, Kalyesubula R, A A, Lettieri D, **Asch W**, Bia M, Formica R, Kulkarni S. 45: Single-Day Work-Up Protocol Is Associated With a Shorter Time to Kidney Transplant: The Yale-New Haven Transplantation Center Experience. American Journal Of Kidney Diseases 2010, 55: b43. [DOI: 10.1053/j.ajkd.2010.02.052](#).
 9. Barrantes F, Arvelakis A, **Asch W**, Coca S, Kalyesubula R, Bia M, Formica R, Kulkarni S. A CENTER COORDINATED, PRE-TRANSPLANT EVALUATION ELIMINATES BARRIERS TO KIDNEY TRANSPLANTATION AND ESTABLISHES PARITY ACROSS ALL SOCIO-ECONOMIC GROUPS. Transplantation 2010, 90: 249. [DOI: 10.1097/00007890-201007272-00471](#).
 10. Kulkarni S, Emre S, Arvelakis A, **Asch W**, Bia M, Formica R, Israel G. Multidetector CT angiography in living donor renal transplantation: accuracy and discrepancies in right venous anatomy. Clinical Transplantation 2011, 25: 77-82. [PMID: 20070320](#), [DOI: 10.1111/j.1399-0012.2009.01193.x](#).
 11. Cimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, **Asch W**, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. [PMID: 21486624](#), [DOI: 10.1016/j.transproceed.2011.02.033](#).
 12. Formica RN, Barrantes F, **Asch WS**, Bia MJ, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Kulkarni S. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. American Journal Of Kidney Diseases 2012, 60: 288-294. [PMID: 22571868](#), [DOI: 10.1053/j.ajkd.2012.04.008](#).
 13. Sullivan PM, **William A**, Tichy EM. Hyperuricemia and gout in solid-organ transplant: update in pharmacological management. Progress In Transplantation (Aliso Viejo, Calif.) 2015, 25: 263-70. [PMID: 26308787](#), [DOI: 10.7182/pit2015322](#).
 14. Waldman AH, McNiff JM, Liapakis A, **Asch WS**, Smith-Marrone S, Colegio OR. Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma. JAAD Case Reports 2015, 1: s8-s11. [PMID: 27051810](#), [PMCID: PMC4809581](#), [DOI: 10.1016/j.jdcr.2015.09.010](#).

15. Guerra CM, Formica RN, Kulkarni S, **Asch WS**, Tichy EM. Duration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients. *Progress In Transplantation* 2015, 25: 311-315. [PMID: 26645924](#), [DOI: 10.7182/pit2015929](#).
16. **Asch W**, Santos S, Peixoto A. Ambulatory Blood Pressure in Patients with Chronic Kidney Disease. 2016, 277-298. [DOI: 10.1007/978-3-319-22771-9_14](#).
17. Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, **Asch W**, Formica R, Kashgarian M, Kulkarni S. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. *Transplantation Proceedings* 2016, 48: 3106-3108. [PMID: 27932157](#), [DOI: 10.1016/j.transproceed.2016.04.005](#).
18. **Asch W**, Stewart D, Formica R. National Kidney Allocation System. 2017 [DOI: 10.2310/nephro.12068](#).
19. Hall IE, Reese PP, Doshi MD, Weng FL, Schröppel B, **Asch WS**, Ficek J, Thiessen-Philbrook H, Parikh CR. Delayed Graft Function Phenotypes and 12-Month Kidney Transplant Outcomes. *Transplantation* 2017, 101: 1913-1923. [PMID: 27495761](#), [PMCID: PMC5292094](#), [DOI: 10.1097/tp.0000000000001409](#).
20. Gabardi S, Pavlakis M, Tan C, Francis J, Cardarelli F, **Asch W**, Bodziak K, Chobanian M, Gilligan H, Gohh R, Kung S, Inker L, Martin S, Rodig N, Rossi A, Chandraker A. New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. *Transplant Infectious Disease* 2018, 20: e12985. [PMID: 30175491](#), [DOI: 10.1111/tid.12985](#).
21. Saffo S, Peng C, Kibbi N, Patel N, Robert ME, Adekolu E, **Asch WS**, Sanchez M. Graft-Versus-Host Disease After Pancreatic Transplantation. *ACG Case Reports Journal* 2019, 6: e00214. [PMID: 31750381](#), [PMCID: PMC6831153](#), [DOI: 10.14309/crj.0000000000000214](#).
22. Harkness TM, Cohen EA, **Asch WS**, Belfield KD. Clinical Implications of Unique Drug Interaction Between Extended Release Tacrolimus and Phenytoin. *Progress In Transplantation* 2020, 30: 177-178. [PMID: 32233829](#), [DOI: 10.1177/1526924820913500](#).
23. Virmani S, Gleeson SE, Gironi GF, Malhotra D, Cohen EA, Klarman SE, **Asch WS**. Identifying a Kidney Transplant Recipient COVID Phenotype to Aid Test Utilization in the Setting of Limited Testing Availability—Does One Exist? *Transplantation Proceedings* 2020, 52: 2584-2591. [PMID: 32711848](#), [PMCID: PMC7305913](#), [DOI: 10.1016/j.transproceed.2020.05.033](#).
24. Johnston JP, Cohen EA, Casal GH, **Asch WS**, Reardon DP. Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant. *Journal Of Pharmacy Practice* 2021, 35: 701-706. [PMID: 33759619](#), [DOI: 10.1177/08971900211000702](#).
25. Azar MM, Cohen E, Ma L, Cissé OH, Gan G, Deng Y, Belfield K, **Asch W**, Grant M, Gleeson S, Koff A, Gaston DC, Topal J, Curran S, Kulkarni S, Kovacs JA, Malinis M. Genetic and Epidemiologic Analyses of an Outbreak of *Pneumocystis jirovecii* Pneumonia Among Kidney Transplant Recipients in the United States. *Clinical Infectious Diseases* 2021, 74: 639-647. [PMID: 34017984](#), [PMCID: PMC9012955](#), [DOI: 10.1093/cid/ciab474](#).
26. Tsai JW, Cerdeña JP, Goedel WC, **Asch WS**, Grubbs V, Mendu ML, Kaufman JS. Evaluating the Impact and Rationale of Race-Specific Estimations of Kidney Function: Estimations from U.S. NHANES, 2015-2018. *EClinicalMedicine* 2021, 42: 101197. [PMID: 34849475](#), [PMCID: PMC8608882](#), [DOI: 10.1016/j.eclinm.2021.101197](#).
27. Sun Z, Zhang Z, Banu K, Azzi YA, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Pell J, Tietjen G, **Asch W**, Kulkarni S, Formica R, Rana M, Zhang W, Akalin E, Cravedi P, Heeger PS, Menon MC.

- Blood transcriptomes of SARS-CoV-2 infected kidney transplant recipients demonstrate immune insufficiency. MedRxiv : The Preprint Server For Health Sciences 2022 [PMID: 35132424](#), [PMCID: PMC8820676](#), [DOI: 10.1101/2022.01.31.22270203](#).
28. **Asch WS**. Is Prioritization of Kidney Allografts to Combined Liver-Kidney Recipients Appropriate? COMMENTARY. *Kidney360* 2022, 3: 999-1002. [PMID: 35849645](#), [PMCID: PMC9255872](#), [DOI: 10.34067/kid.0005042021](#).
 29. Sun Z, Zhang Z, Banu K, Azzi YA, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Kim Y, Pell J, Tietjen G, **Asch W**, Kulkarni S, Formica R, Rana M, Maltzman JS, Zhang W, Akalin E, Heeger PS, Cravedi P, Menon MC. Blood Transcriptomes of SARS-CoV-2–Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity. *Journal Of The American Society Of Nephrology* 2022, 33: 2108-2122. [PMID: 36041788](#), [PMCID: PMC9678030](#), [DOI: 10.1681/asn.2022010125](#).

Peer-Reviewed Original Research In Press

1. Asch WS. Is prioritization of kidney allografts to combined liver-kidney recipients appropriate? Discussion of the Pros and Cons. *Kidney360*, In Press, 2021

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Frascà GM, Sandrini S, Cosmai L, Porta C, **Asch W**, Santoni M, Salviani C, D’Errico A, Malvi D, Balestra E, Gallieni M. Renal cancer in kidney transplanted patients. *Journal Of Nephrology* 2015, 28: 659-668. [PMID: 26202137](#), [DOI: 10.1007/s40620-015-0219-8](#).
2. Deshpande R, **Asch W**, Malinis M. Frailty and Perioperative Outcomes. *Current Anesthesiology Reports* 2018, 8: 225-231. [DOI: 10.1007/s40140-018-0275-4](#).

Books

1. Asch, W.S. and Lifton R.P. Molecular genetics of magnesium homeostasis. In *Genetic Diseases of the Kidney* Eds. R.P Lifton, S. Somlo, G. Giebisch, D. Seldin. Elsevier/Academic Press, San Diego, CA. 2009 pp. 249-261
2. Vigneault CB, **Asch WS**, Dahl NK, Bia MJ. Should Living Kidney Donor Candidates with Impaired Fasting Glucose Donate? *Clinical Journal Of The American Society Of Nephrology* 2011, 6: 2054-2059. [PMID: 21784837](#), [DOI: 10.2215/cjn.03370411](#).
3. **Asch WS**, Bia M. When should nephrectomy be performed for a failed renal transplant? *Seminars In Dialysis* 2011, 24: 374-376. [PMID: 21801221](#), [DOI: 10.1111/j.1525-139x.2011.00903.x](#).
4. **Asch WS**, Bia MJ. Oncologic Issues and Kidney Transplantation: A Review of Frequency, Mortality, and Screening. *Advances In Kidney Disease And Health* 2014, 21: 106-113. [PMID: 24359993](#), [DOI: 10.1053/j.ackd.2013.07.003](#).
5. 21. Asch WS, Santos SFF, Peixoto AJ. Ambulatory blood pressure in patients with chronic kidney disease. In *Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics, Clinical Hypertension and Vascular Diseases*. Ed. William B. White. Humana Press Inc., New York, NY. 2015.

6. 24. Nemr, Saed, and Asch, WS. "Kidney Transplantation." In: CURRENT Diagnosis Treatment: Nephrology Hypertension, 2e Eds. Edgar V. Lerma, et al. New York, NY: McGraw-Hill. 2017
7. Virmani S, **Asch WS**. The Role of the General Nephrologist in Evaluating Patients for Kidney Transplantation: Core Curriculum 2020. American Journal Of Kidney Diseases 2020, 76: 567-579. [PMID: 32199707](#), [DOI: 10.1053/j.ajkd.2020.01.001](#).

Commentaries, Editorials and Letters

1. **Asch WS**, Bia MJ. Patient Education to Reduce Disparities in Renal Transplantation. Clinical Journal Of The American Society Of Nephrology 2012, 7: 527-529. [PMID: 22403275](#), [DOI: 10.2215/cjn.01770212](#).
2. **Asch WS**, Perazella MA. Cancer and Mortality in Solid-Organ Transplantation: Preventable or Inevitable? American Journal Of Kidney Diseases 2016, 68: 839-842. [PMID: 27405594](#), [DOI: 10.1053/j.ajkd.2016.06.009](#).
3. **Asch WS**, Bia MJ. New Organ Allocation System for Combined Liver-Kidney Transplants and the Availability of Kidneys for Transplant to Patients with Stage 4–5 CKD. Clinical Journal Of The American Society Of Nephrology 2016, 12: 848-852. [PMID: 28028050](#), [PMCID: PMC5477211](#), [DOI: 10.2215/cjn.08480816](#).
4. **Asch WS**. Is Hypertension Following Donor Nephrectomy Cause For Elevated Living Donor Kidney Function Concern? Clinical Journal Of The American Society Of Nephrology 2019, 14: 1427-1429. [PMID: 31591256](#), [PMCID: PMC6777590](#), [DOI: 10.2215/cjn.09650819](#).